Abstract graphic of an eye
Investor Relations

Press Releases

Press release
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
September 18, 2024
Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development HOLLISTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest
Press release
Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference
September 5, 2024
HOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Small Cap Virtual Conference on September 18 th , 2024,
Press release
Harvard Bioscience Announces Second Quarter 2024 Financial Results
August 8, 2024
HOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2024. Jim Green, Chairman and CEO, said, “Second quarter revenues reflect a more challenging than expected market
Press release
Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET
August 2, 2024
HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to discuss the results at 10:00 a.m.
Press release
Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
June 6, 2024
HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14 th Annual East Coast IDEAS Conference at the Jay
Press release
Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024
May 23, 2024
HOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriott
Press release
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
May 16, 2024
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22 nd ,
Press release
Harvard Bioscience Announces First Quarter 2024 Financial Results
May 7, 2024
Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024.
Press release
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
April 29, 2024
HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m.
Press release
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
April 9, 2024
HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately
Displaying 1 - 10 of 14